Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-vbsjw Total loading time: 0 Render date: 2025-04-28T20:13:30.133Z Has data issue: false hasContentIssue false

17 - New Concepts in Targeting and Imaging Liver Cancer

from PART III - ORGAN-SPECIFIC CANCERS

Published online by Cambridge University Press:  18 May 2010

By
Eleni Liapi ,
Christos S. Georgiades ,
Kelvin Hong  and
Jean-Francois H. Geschwind
Edited by
Jean-François H. Geschwind  and
Michael C. Soulen
Eleni Liapi
Affiliation:
Postdoctoral Research Fellow, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD
Christos S. Georgiades
Affiliation:
Assistant Professor, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD
Kelvin Hong
Affiliation:
Assistant Professor, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD
Jean-Francois H. Geschwind
Affiliation:
Professor of Radiology, Department of Radiology and Radiological Science Johns Hopkins University School of Medicine Baltimore, MD
Jean-François H. Geschwind
Affiliation:
The Johns Hopkins University School of Medicine
Michael C. Soulen
Affiliation:
University of Pennsylvania School of Medicine
Get access

Summary

Ongoing research in the discipline of image-guided interventional oncology for hepatic malignancies seeks to discover and implement novel and effective therapeutic approaches in order to benefit patients with unresectable liver cancer. Research in this area incorporates advancements in the knowledge of liver cancer biology, new concepts in targeting liver cancer, development of novel drugs, improvement of intra-arterial drug delivery and technological advances of imaging systems.

This chapter is an overview of the most recent knowledge in liver cancer biology, new locoregional therapies for liver cancer and new imaging concepts for monitoring locoregional treatment response.

NEW CONCEPTS IN TARGETING LIVER CANCER

Targeting Angiogenesis

The fundamental role of angiogenesis in tumor progression was first suggested by Folkman et al. in a classic study describing that tumors cannot grow beyond 1 mm or 2 mm without the formation of new blood vessels (1). This complex process facilitates tumor progression and, eventually, tumor metastatic spread (1, 2). Several factors, including tumor hypoxia, growth factors, cytokines, oncogene activation and other mutations interact to stimulate angiogenesis (2, 3). Therefore, targeted inhibition of angiogenesis can be achieved at any of the aforementioned different levels, with treatments including the neutralization of growth factors with monoclonal antibodies (mAbs), the inhibition of downstream signaling from tyrosine kinase receptors and interference with the interaction between proliferating endothelial cells and matrix components.

Hepatocellular carcinoma (HCC) is one of the most vascular solid cancers, associated with a high propensity for vascular invasion.

Type
Chapter
Information
Interventional Oncology
Principles and Practice
 , pp. 202 - 212
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Folkman, J. Tumor angiogenesis: Therapeutic implications. N Engl J Med, 1971; 285(21): 1182–1186.Google ScholarPubMed
Yancopoulos, G D, Davis, S, Gale, N W, et al. Vascular-specific growth factors and blood vessel formation. Nature, 2000; 407(6801): 242.CrossRefGoogle ScholarPubMed
Bergers, G and Benjamin, L E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 2003 Jun; 3(6): 401–410.CrossRefGoogle Scholar
Ferrara, N and Henzel, W J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989; 161(2): 851–858.CrossRefGoogle ScholarPubMed
Hicklin, D J and Ellis, L M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 2005; 23(5): 1011–1027.CrossRefGoogle ScholarPubMed
Dvorak, H F, Brown, L F, Detmar, M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 1995; 146(5): 1029–1039.Google ScholarPubMed
Ferrara, N. Vascular endothelial growth factor: Molecular and biological aspects. Curr Top Microbiol Immunol, 1999; 237: 1–30.Google ScholarPubMed
Schneider, B P and Miller, K D. Angiogenesis of breast cancer. J Clin Oncol, 2005 Mar 10; 23(8): 1782–90.CrossRefGoogle Scholar
Fan, F, Wey, J S, McCarty, M F, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene, 2005; 24(16): 2647–2653.CrossRefGoogle ScholarPubMed
Jeng, K S, Sheen, I S, Wang, Y C, et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: A prospective study. World J Gastroenterol, 2004; 10(5): 643–648.CrossRefGoogle ScholarPubMed
Ng, I O, Poon, R T, Lee, J M, et al. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol, 2001; 116(6): 838–845.CrossRefGoogle ScholarPubMed
Yao, D F, Wu, X H, Zhu, Y, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2005; 4(2): 220–6.Google ScholarPubMed
Takahashi, Y, Kitadai, Y, Bucana, C D, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res, 1995; 55(18): 3964–3968.Google ScholarPubMed
Kim, K J, Li, B, Winer, J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 1993; 362(6423): 841–844.CrossRefGoogle ScholarPubMed
Levene, A P, Singh, G, Palmieri, C. Therapeutic monoclonal antibodies in oncology. J R Soc Med, 2005 Apr 1; 98(4): 146–152.CrossRefGoogle Scholar
Wang, Y, Fei, D, Vanderlaan, M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 2004; 7(4): 335.CrossRefGoogle ScholarPubMed
Motl, S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm, 2005; 62(10): 1021–1032.Google ScholarPubMed
Food and Drug Administration. Bevacizumab FDA approval letter, 2004.
Cobleigh, M A, Langmuir, V K, Sledge, G W, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol, 2003; 30(5 Suppl 16): 117–124.CrossRefGoogle ScholarPubMed
Yang, J C, Haworth, L, Sherry, R M, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003; 349(5): 427–434.CrossRefGoogle ScholarPubMed
Kerr, C. Bevacizumab and chemotherapy improves survival in NSCLC. The Lancet Oncology, 2005; 6(5): 266.CrossRefGoogle ScholarPubMed
Petrylak, D P. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology, 2005; 65(5, Supplement 1): 3.CrossRefGoogle ScholarPubMed
Rini, B I. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist, 2005; 10(3): 191–197.CrossRefGoogle ScholarPubMed
Imaeda, T, Kanematsu, M, Mochizuki, R, et al. Extracapsular invasion of small hepatocellular carcinoma: MR and CT findings. J Comput Assist Tomogr, 1994; 18(5): 755–760.CrossRefGoogle ScholarPubMed
Yamaguchi, R, Yano, H, Iemura, A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, 1998; 28(1): 68–77.CrossRefGoogle ScholarPubMed
Graepler, F, Gregor, M, and Lauer, U M. [Anti-angiogenic therapy for gastrointestinal tumours]. Z Gastroenterol, 2005; 43(3): 317–329.CrossRefGoogle Scholar
Schwartz, JD SM, Lehrer, D, Coll, D. Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein. Orlando, Florida: American Society of Clinical Oncology, Gastrointestinal Cancers Symposium; 2005.Google Scholar
Britten, C, Finn, R S, Gomes, A S. A pilot study of IV bevacizumab in hepatocellular carcinoma patients undergoing chemoembolization. ASCO Annual Meeting; Orlando, Florida, 2005.Google Scholar
Geschwind, J F. Bevacizumab and Chemoembolization in Treating Patients with Liver Cancer that Cannot Be Removed by Surgery. National Cancer Institute Clinical Trials Database, accessed 30/12/2007.
Britten, C. A Phase II Study of rhuMAb VEGF (Bevacizumab) in Patients with Hepatocellular Carcinoma Receiving Chemoembolization. National Cancer Institute (NCI) Database, accessed 30/12/2007.
Peck-Radosavljevic, M. Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma. National Cancer Institute (NCI), 2007.Google Scholar
Warburg, O. On the origin of cancer cells. Science, 1956; 123(3191): 309–314.CrossRefGoogle ScholarPubMed
Rempel, A, Mathupala, S P, Griffin, C A, et al. Glucose catabolism in cancer cells: Amplification of the gene encoding type II hexokinase. Cancer Res, 1996; 56(11): 2468–2471.Google ScholarPubMed
Shinohara, Y, Ichihara, J, Terada, H. Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130. FEBS Letters, 1991; 291(1): 55.CrossRefGoogle ScholarPubMed
Yasuda, S, Arii, S, Mori, A, et al. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor-1[alpha] and its significance. J Hepatol, 2004; 40(1): 117.CrossRefGoogle ScholarPubMed
Gwak, G-Y, Yoon, J-H, Kim, K M, et al. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol, 2005; 42(3): 358.CrossRefGoogle ScholarPubMed
Geschwind, J- F H, Ko, Y H, Torbenson, M S, et al. Novel therapy for lver cancer: Direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res, 2002; 62(14): 3909–3913.Google Scholar
Geschwind, J F, Georgiades, C S, Ko, Y H, et al. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther, 2004; 449–457.CrossRefGoogle ScholarPubMed
Foubister, V. Energy blocker to treat liver cancer. Drug Discovery Today, 2002; 7(18): 934.CrossRefGoogle ScholarPubMed
Leist, M, Single, B, Castoldi, A F, et al. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis. J Exp Med, 1997; 185(8): 1481–1486.CrossRefGoogle ScholarPubMed
Xu, R-H, Pelicano, H, Zhou, Y, et al. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res, 2005; 65(2): 613–621.Google ScholarPubMed
Llovet, J M, Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 2003; 37(2): 429–442.CrossRefGoogle ScholarPubMed
Lo, C M, Ngan, H, Tso, W K, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002; 35(5): 1164–1171.CrossRefGoogle ScholarPubMed
Yang, Z F, Poon, R T, To, J, et al. The potential role of hypoxia inducible factor-1{alpha} in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res, 2004; 64(15): 5496–5503.CrossRefGoogle ScholarPubMed
Tanaka, H, Yamamoto, M, Hashimoto, N, et al. hypoxia-independent overexpression of hypoxia-inducible factor -{alpha} as an early change in mouse hepatocarcinogenesis. Cancer Res, 2006; 66(23): 11263–11270.CrossRefGoogle ScholarPubMed
Kim, Y I, Chung, J W, Park, J H, et al. Intraarterial gene delivery in rabbit hepatic tumors: Transfection with nonviral vector by using iodized oil emulsion. Radiology, 2006; 240(3): 771–777.CrossRefGoogle ScholarPubMed
Iwasaki, Y, Ueda, M, Yamada, T, et al. Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Ther, 2006; 14(1): 74–81.CrossRefGoogle ScholarPubMed
Reid, T, Warren, R, Kirn, D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther, 2002; 9(12): 979–986.CrossRefGoogle ScholarPubMed
Reid, T, Galanis, E, Abbruzzese, J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther, 2001; 8(21): 1618–1626.CrossRefGoogle ScholarPubMed
Qian, J, Truebenbach, J, Graepler, F, et al. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. World J Gastroenterol, 2003; 9(1): 94–98.CrossRefGoogle Scholar
Constantin, M, Fundueanu, G, Bortolotti, F, et al. Preparation and characterisation of poly(vinyl alcohol)/cyclodextrin microspheres as matrix for inclusion and separation of drugs. Int J Pharm, 2004; 285(1–2): 87–96.CrossRefGoogle ScholarPubMed
Vallee, J N, Lo, D, Guillevin, R, et al. In vitro study of the compatibility of tris-acryl gelatin microspheres with various chemotherapeutic agents. J Vasc Interv Radiol, 2003; 14(5): 621–628.CrossRefGoogle ScholarPubMed
Fujiwara, K, Hayakawa, K, Nagata, Y, et al. Experimental embolization of rabbit renal arteries to compare the effects of poly L-lactic acid microspheres with and without epirubicin release against intraarterial injection of epirubicin. Cardiovasc Intervent Radiol, 2000; 23(3): 218–223.CrossRefGoogle ScholarPubMed
Varela, M, Real, M I, Burrel, M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol, 2007; 46(3): 474–481.CrossRefGoogle ScholarPubMed
Lewis, A L, Gonzalez, M V, Lloyd, A W, et al. DC bead: In vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol, 2006; 17(2): 335–342.CrossRefGoogle Scholar
Taylor, R R, Tang, Y, Gonzalez, M V, et al. Irinotecan drug eluting beads for use in chemoembolization: In vitro and in vivo evaluation of drug release properties. Eur J Pharma Sci, 2007; 30(1): 7–14.CrossRefGoogle ScholarPubMed
Hong, K, Khwaja, A, Liapi, E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: Preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res, 2006; 12(8): 2563–2567.CrossRefGoogle Scholar
Taylor, R R, Tang, Y, Gonzalez, M V, et al. Irinotecan drug eluting beads for use in chemoembolization: In vitro and in vivo evaluation of drug release properties. Eur J Pharma Sci, 2007; 30(1): 7–14.CrossRefGoogle ScholarPubMed
Aliberti, C, Tilli, M, Benea, G, et al. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: Preliminary results. Anticancer Res, 2006; 26(5B): 3793–3795.Google Scholar
Yukio, I, Kouichirou, T, Shigeru, G, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunology, Immunotherapy, 2003; 52(3): 155–161.Google Scholar
Nijsen, J F, Zonnenberg, B A, Woittiez, J R, et al. Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med, 1999; 26(7): 699–704.CrossRefGoogle ScholarPubMed
Mumper, R J, Yun, Ryo U, Jay, M. Neutron-activated holmium-166-poly (L-lactic acid) microspheres: A potential agent for the internal radiation therapy of hepatic tumors. J Nucl Med, 1991; 32(11): 2139–2143.Google ScholarPubMed
Kim, J K, Han, K-H, Lee, J T, et al. Long-term clinical outcome of Phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res, 2006; 12(2): 543–548.CrossRefGoogle ScholarPubMed
Hamstra, D A, Chenevert, T L, Moffat, B A, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. PNAS, 2005; 102(46): 16759–16764.CrossRefGoogle ScholarPubMed
Hall, D E, Moffat, B A, Stojanovska, J, et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res, 2004; 10(23): 7852–7859.CrossRefGoogle ScholarPubMed
Kamel, I R, Bluemke, D A, Eng, J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol, 2006; 17(3): 505–512.CrossRefGoogle ScholarPubMed
Sakurai, M, Okamura, J, Kuroda, C. Transcatheter chemo-embolization effective for treating hepatocellular carcinoma. A histopathologic study. Cancer, 1984; 54(3): 387–392.3.0.CO;2-W>CrossRefGoogle ScholarPubMed
Di, Carlo V, Ferrari, G, Castoldi, R, et al. Pre-operative chemoembolization of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology, 1998; 45(24): 1950–1954.Google Scholar
Paye, F, Jagot, P, Vilgrain, V, et al. Preoperative chemoembolization of hepatocellular carcinoma: A comparative study. Arch Surg, 1998; 133(7): 767–772.CrossRefGoogle ScholarPubMed
Miller, J C, Pien, H H, Sahani, D, et al. Imaging angiogenesis: Applications and potential for drug development. J Natl Cancer Inst, 2005; 97(3): 172–187.CrossRefGoogle ScholarPubMed
Padhani, A R, Leach, M O. Antivascular cancer treatments: Functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdominal Imaging, 2005; 30(3): 325–342.CrossRefGoogle ScholarPubMed
Juweid, M E, Cheson, B D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med, 2006; 354(5): 496–507.CrossRefGoogle ScholarPubMed
Jaffe, C C. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol, 2006; 24(20): 3245–3251.CrossRefGoogle ScholarPubMed
Patrick, V, Gerald, A, Hrvoje, S, et al. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: Initial results. Eur Radiol, 2006; 16(1): 80–87.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • New Concepts in Targeting and Imaging Liver Cancer
    • By Eleni Liapi, Postdoctoral Research Fellow, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD, Christos S. Georgiades, Assistant Professor, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD, Kelvin Hong, Assistant Professor, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD, Jean-Francois H. Geschwind, Professor of Radiology, Department of Radiology and Radiological Science Johns Hopkins University School of Medicine Baltimore, MD
  • Edited by Jean-François H. Geschwind, The Johns Hopkins University School of Medicine, Michael C. Soulen, University of Pennsylvania School of Medicine
  • Book: Interventional Oncology
  • Online publication: 18 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511722226.018
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • New Concepts in Targeting and Imaging Liver Cancer
    • By Eleni Liapi, Postdoctoral Research Fellow, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD, Christos S. Georgiades, Assistant Professor, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD, Kelvin Hong, Assistant Professor, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD, Jean-Francois H. Geschwind, Professor of Radiology, Department of Radiology and Radiological Science Johns Hopkins University School of Medicine Baltimore, MD
  • Edited by Jean-François H. Geschwind, The Johns Hopkins University School of Medicine, Michael C. Soulen, University of Pennsylvania School of Medicine
  • Book: Interventional Oncology
  • Online publication: 18 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511722226.018
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • New Concepts in Targeting and Imaging Liver Cancer
    • By Eleni Liapi, Postdoctoral Research Fellow, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD, Christos S. Georgiades, Assistant Professor, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD, Kelvin Hong, Assistant Professor, Department of Radiology and Radiological Science Division of Cardiovascular and Interventional Radiology Johns Hopkins University School of Medicine Baltimore, MD, Jean-Francois H. Geschwind, Professor of Radiology, Department of Radiology and Radiological Science Johns Hopkins University School of Medicine Baltimore, MD
  • Edited by Jean-François H. Geschwind, The Johns Hopkins University School of Medicine, Michael C. Soulen, University of Pennsylvania School of Medicine
  • Book: Interventional Oncology
  • Online publication: 18 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511722226.018
Available formats
×